Abstract
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease characterized by T-cell, B-cell, and dendritic cell dysfunction and antinuclear autoantibody production. Much of the knowledge that has been gained about SLE in recent years is related to molecular signaling abnormalities present in the disease. Signaling through the T-cell receptor (TCR) is affected in SLE by alterations in the localization, amount, and activity of numerous protein kinases. TCR stimulation releases calcium from intracellular stores, which triggers an influx of extracellular calcium and activates the transcription of many genes, including interleukin-2. Short-term calcium fluxing is exaggerated in SLE, but long-term calcium fluxing is diminished and may account for sub-optimal interleukin-2 production. SLE T-cells have persistently hyperpolarized mitochondria associated with increased mitochondrial mass, high levels of reactive oxygen species (ROS) and low levels of ATP, which decrease activation-induced apoptosis and instead predispose T cells for necrosis, thus stimulating inflammation in SLE. The pentose phosphate pathway impacts the mitochondrial potential and represents a target for possible intervention. Nitric oxide (NO) is a potential link to tie together the signaling and mitochondrial abnormalities in SLE. NO-induced mitochondrial biogenesis recapitulates the TCR-stimulated calcium fluxing abnormalities of SLE T-cells. Since mitochondria can store calcium, the increase in mitochondrial mass may be implicated in the aberrant calcium fluxing in SLE T cells. The mammalian target of rapamycin senses the mitochondrial potential and regulates calcium release, serving as a novel target of treatment of SLE.
Keywords: Lupus, mitochondria, mitochondrial hyperpolarization, nitric oxide, calcium, mTOR, glutathione
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets
Volume: 6 Issue: 4
Author(s): David Fernandez, Eduardo Bonilla, Paul Phillips and Andras Perl
Affiliation:
Keywords: Lupus, mitochondria, mitochondrial hyperpolarization, nitric oxide, calcium, mTOR, glutathione
Abstract: Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease characterized by T-cell, B-cell, and dendritic cell dysfunction and antinuclear autoantibody production. Much of the knowledge that has been gained about SLE in recent years is related to molecular signaling abnormalities present in the disease. Signaling through the T-cell receptor (TCR) is affected in SLE by alterations in the localization, amount, and activity of numerous protein kinases. TCR stimulation releases calcium from intracellular stores, which triggers an influx of extracellular calcium and activates the transcription of many genes, including interleukin-2. Short-term calcium fluxing is exaggerated in SLE, but long-term calcium fluxing is diminished and may account for sub-optimal interleukin-2 production. SLE T-cells have persistently hyperpolarized mitochondria associated with increased mitochondrial mass, high levels of reactive oxygen species (ROS) and low levels of ATP, which decrease activation-induced apoptosis and instead predispose T cells for necrosis, thus stimulating inflammation in SLE. The pentose phosphate pathway impacts the mitochondrial potential and represents a target for possible intervention. Nitric oxide (NO) is a potential link to tie together the signaling and mitochondrial abnormalities in SLE. NO-induced mitochondrial biogenesis recapitulates the TCR-stimulated calcium fluxing abnormalities of SLE T-cells. Since mitochondria can store calcium, the increase in mitochondrial mass may be implicated in the aberrant calcium fluxing in SLE T cells. The mammalian target of rapamycin senses the mitochondrial potential and regulates calcium release, serving as a novel target of treatment of SLE.
Export Options
About this article
Cite this article as:
Fernandez David, Bonilla Eduardo, Phillips Paul and Perl Andras, Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187153006779025748
DOI https://dx.doi.org/10.2174/187153006779025748 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Penicillium marneffei and its Pulmonary Involvements
Current Respiratory Medicine Reviews Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology Metastatic Melanoma in a Young Woman Treated with TNF-Alpha Inhibitor for Psoriatic Arthritis: A Case Report
Current Drug Safety Emerging Facts on Chronic Consumption of Aspartame as Food Additive
Current Nutrition & Food Science SNAP-tag based Agents for Preclinical In Vitro Imaging in Malignant Diseases
Current Pharmaceutical Design MicroRNAs: A Novel Non-Invasive Biomarker for Patients with Urological Malignancies
Current Pharmaceutical Biotechnology Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development
Current Pharmaceutical Design Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine Photopheresis in HIV-1 Infected Patients Utilizing Benzoporphyrin Derivative (BPD) Verteporfin and Light
Current HIV Research Exploring Confluence-Related Signalling to Modulate the Expression of Oct4 – A Role in Facilitating Mouse Somatic Cell Reprogramming?
Current Stem Cell Research & Therapy Transbronchial Needle Aspiration (TBNA): Past Present and Future
Current Respiratory Medicine Reviews Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets